What Lilly and Novo's Q2 Results Mean

Eli Lilly and Novo Nordisk reported very different second-quarter 2026 headlines, but the gap says more about sales momentum and investor expectations than it does about whether one medicine works for an individual patient. BioPharma Dive reported that Lilly's quarterly revenue rose 48% to nearly $23 billion, ahead of the $20.6 billion analyst consensus, while Novo faced a weaker-than-expected quarter for the Wegovy pill and disappointing CagriSema trial news^[1]. The useful reading is not simply that Lilly won and Novo lost. It is that the obesity market now rewards launch execution, prescription growth, and evidence against competing products at the same time.

The numbers behind the split

Lilly's quarter was carried by its injectable tirzepatide franchise, sold as Mounjaro for diabetes and Zepbound for obesity in the United States. BioPharma Dive reported that the franchise again beat analyst expectations and helped Lilly raise its 2026 revenue forecast to between $85 billion and $87 billion, from $82 billion to $85 billion^[1]. Novo also improved its outlook, but from a weaker base. The company said adjusted 2026 sales growth at constant exchange rates would range from flat to a 6% decline, an improvement on its previous forecast^[2].

Novo's own release reported Q2 net sales of DKK 78.488 billion and adjusted operating profit of DKK 33.389 billion. Adjusted sales rose 7% at constant exchange rates, which means the calculation removes currency movements to show the underlying business trend^[2]. That is growth, not collapse. The market reaction reflected the difference between a company improving slowly and a rival growing faster than analysts expected.

Why the pill launch drew attention

Novo had an early oral advantage with the Wegovy pill, an oral version of semaglutide. BioPharma Dive reported second-quarter pill sales of DKK 3.2 billion, below the DKK 3.6 billion analyst estimate. Lilly's Foundayo pill also missed its consensus estimate, with sales of $98 million against an expected $104 million, but investors reacted less sharply^[1]. A miss against a forecast is not the same as a failed launch. It means actual sales came in below the outside estimate used to judge the quarter.

Novo said the Wegovy pill had passed 5 million prescriptions since launch and exceeded 265,000 total weekly prescriptions in the week ending July 17. It also reported launches in the United Arab Emirates and the United Kingdom, with more markets planned^[2]. Those figures show real uptake even though quarterly revenue fell short of analysts' model. They also explain why a single sales estimate should not be read as a verdict on the medicine itself.

The medicines are not interchangeable

The company rivalry can blur an important clinical distinction. Wegovy contains semaglutide, a GLP-1 receptor agonist. The European Medicines Agency lists it as an authorised weight-management medicine used alongside diet and physical activity for eligible adults and adolescents^[3]. Mounjaro contains tirzepatide, which acts at both GIP and GLP-1 receptors. The EMA lists Mounjaro for type 2 diabetes and for weight management in eligible adults^[4]. Shared commercial competition does not make the molecules, approved indications, or treatment decisions identical.

That distinction also applies to brands and formulations. Readers can use our semaglutide regulation overview and tirzepatide regulation overview to separate the active substances from regional brand names and authorisation status. An earnings release answers what a company sold. A medicine regulator answers what a product contains and what it is authorised to treat.

What this is not

This quarter does not prove that tirzepatide is the right medicine for every person, or that semaglutide has stopped working. It does not compare adverse effects, long-term outcomes, access, or individual contraindications. The stock moves described by BioPharma Dive followed company reports, analyst estimates, and a separate head-to-head diabetes trial involving Novo's experimental CagriSema combination^[1]. Those are several different questions compressed into one market story.

The cleanest interpretation is commercial. Lilly entered the quarter with stronger injectable momentum and exceeded the revenue bar set by analysts. Novo reported growing GLP-1 demand and raised its outlook, yet still disappointed on a closely watched pill estimate and on pipeline evidence. Investors price the gap between expectations and results, not only the absolute number of prescriptions or the clinical value of an approved medicine.

What we do not yet know

One quarter cannot show how the oral obesity market will divide over time. Novo is expanding the Wegovy pill beyond the United States, while both companies are building broader portfolios around injections and tablets^[1][2]. Future competition will depend on supply, insurance coverage, pricing, real-world persistence, safety findings, and comparative trial data. None of those can be settled by a two-day share-price reaction.

Why this matters

Obesity-drug earnings stories often turn company performance into a simple medicine ranking. That shortcut is attractive and wrong. For readers, the better split is straightforward: use financial reports to understand market momentum, regulator documents to understand authorised uses, and clinical evidence to compare outcomes. A prescribing decision should be made with a qualified clinician who can weigh medical history, access, and the actual product information, not with a quarterly sales table.